Neridronic acid

Drug GRT US Holding, Inc.
Total Payments
$2.7M
Transactions
503
Doctors
6
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2020 $413,579 106 0
2019 $2.3M 397 6

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $2.7M 503 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
KF7013-04 GRT US Holding, Inc. $1.6M 3
KF7013-02 GRT US Holding, Inc. $1.1M 3

Top Doctors Receiving Payments for Neridronic acid

Doctor Specialty Location Total Records
Unknown Flint, MI $2.4M 487
, MD Cardiovascular Disease Los Angeles, CA $257,402 5
, MD Psychiatry Panorama City, CA $50,190 3
, M.D Neurology Boca Raton, FL $40,339 5
, MD Pain Medicine Colton, CA $6,000 1
, M.D Interventional Pain Medicine Frisco, TX $5,167 1
, M.D Neurology Suwanee, GA $3,214 1

About Neridronic acid

Neridronic acid is a drug associated with $2.7M in payments to 6 healthcare providers, recorded across 503 transactions in the CMS Open Payments database. The primary manufacturer is GRT US Holding, Inc..

Payment data is available from 2019 to 2020. In 2020, $413,579 was paid across 106 transactions to 0 doctors.

The most common payment nature for Neridronic acid is "Unspecified" ($2.7M, 100.0% of total).

Neridronic acid is associated with 2 research studies, including "KF7013-04" ($1.6M).